An error has occurred in processing the XML document
Good Clinical Practice (GCP) requires that all clinical trial information shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified.
Essential documents are:
"...those which enable both the conduct of the clinical trial and the quality of the data produced to be evaluated; and show whether the trial is, or has been, conducted in accordance with the applicable regulatory requirements"
Many essential documents are filed in a Trial Master File / Investigator Site File. Some, essential documents may also be source documents, which are often generated as part of the subject’s medical care and therefore documented and archived in medical records and other service departments.
The European Commission has published Detailed Guidance on the Content of a Trial Master File and Archiving (PDF, 279 KB) and is primarily based on ICH GCP E6 Section 8. This document includes an explanation of the purpose of each essential document and whether it should be retained by the sponsor, the investigational site or both.
Electronic Source Data
Source data and other essential documents may be kept in either paper or electronic format. The EMA published a document in 2010: Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials (PDF, 127 KB).
For sites considering a move from paper medical records to electronic health records (eHR), the MHRA have produced a position statement on the implementation of eHR systems to ensure compliance with the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). The position statement details common problems found with eHR systems during GCP inspection and provides a comprehensive list of factors to consider when trial sites are establishing an eHR system.
A number of European Commission Guidance Documents have been published which serve to illustrate what would be evaluated during an inspection of a clinical trial and therefore what documentation would be required to enable that evaluation (see Chapter IV- Inspections: Annex I-V).